Company Profile For XenoPort, Inc.

XenoPort, Inc. (XNPT.O) (Nasdaq)

sector: Healthcare · industry: Pharmaceuticals - Generic & Specialty ·

As of 10:56pm IST

16.26USD

Price Change

+0.06

Percent Change

+0.37%

Analyst Recommendations

Overview

XenoPort, Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. The Company focuses on development and commercialization efforts on potential treatments of central nervous system (CNS), disorders. Its product candidate, XP13512, known in the United States by the trade name Solzira (gabapentin enacarbil) Extended Release Tablets, is being developed for the treatment of a number of CNS disorders. During the year ended December 31, 2008, XP13512 completed a Phase IIa clinical trial for the management of post-herpetic neuralgia (PHN), in the United States.

Quick Financial Synopsis

BRIEF: For the nine months ended 30 September 2009, Xenoport, Inc.'s revenues decreased 9% to $28.5M. Net loss increased 10% to $48M. Revenues reflect decreased collaboration revenues and lower income from unconsolidated joint operating activities. Net loss was offset by increased selling, general and administrative expenses, lower interest income and decreased income tax benefit.